Literature DB >> 25204570

Value of routine 'day 14' marrow exam in newly diagnosed AML.

T Yezefski1, H Xie2, R Walter3, J Pagel4, P S Becker3, P Hendrie5, V Sandhu2, K Shannon-Dorcy2, J Abkowitz5, F R Appelbaum4, E Estey3.   

Abstract

Entities:  

Mesh：

Year:  2014        PMID： 25204570     DOI： 10.1038/leu.2014.268

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  7 in total

1.  Acute myeloid leukemia, version 2.2013.

Authors:  Margaret R O'Donnell; Martin S Tallman; Camille N Abboud; Jessica K Altman; Frederick R Appelbaum; Daniel A Arber; Eyal Attar; Uma Borate; Steven E Coutre; Lloyd E Damon; Jeffrey Lancet; Lori J Maness; Guido Marcucci; Michael G Martin; Michael M Millenson; Joseph O Moore; Farhad Ravandi; Paul J Shami; B Douglas Smith; Richard M Stone; Stephen A Strickland; Eunice S Wang; Kristina M Gregory; Maoko Naganuma
Journal:  J Natl Compr Canc Netw       Date:  2013-09-01       Impact factor: 11.908

2.  Rapid rate of peripheral blood blast clearance accurately predicts complete remission in acute myeloid leukemia.

Authors:  V Vainstein; S A Buckley; O Shukron; E H Estey; J L Abkowitz; B L Wood; R B Walter
Journal:  Leukemia       Date:  2013-11-18       Impact factor: 11.528

3.  Kinetics of bone marrow blasts during induction and achievement of complete remission in acute myeloid leukemia.

Authors:  Masamitsu Yanada; Gautam Borthakur; Farhad Ravandi; Carlos Bueso-Ramos; Hagop Kantarjian; Elihu Estey
Journal:  Haematologica       Date:  2008-06-02       Impact factor: 9.941

4.  Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study.

Authors:  M L Slovak; K J Kopecky; P A Cassileth; D H Harrington; K S Theil; A Mohamed; E Paietta; C L Willman; D R Head; J M Rowe; S J Forman; F R Appelbaum
Journal:  Blood       Date:  2000-12-15       Impact factor: 22.113

Review 5.  New strategies for the evaluation of the nadir bone marrow following induction in acute myeloid leukemia.

Authors:  Ryan J Mattison; Selina M Luger; Hillard M Lazarus
Journal:  Curr Opin Hematol       Date:  2013-03       Impact factor: 3.284

6.  Re-induction therapy decisions based on day 14 bone marrow biopsy in acute myeloid leukemia.

Authors:  Tod A Morris; Carlos M DeCastro; Louis F Diehl; Jon P Gockerman; Anand S Lagoo; Zhiguo Li; Joseph O Moore; David A Rizzieri; Arati V Rao
Journal:  Leuk Res       Date:  2012-10-07       Impact factor: 3.156

7.  Day 14 bone marrow biopsy in predicting complete remission and survival in acute myeloid leukemia.

Authors:  Kebede Hussein; Balkrishna Jahagirdar; Pankaj Gupta; Linda Burns; Karen Larsen; Daniel Weisdorf
Journal:  Am J Hematol       Date:  2008-06       Impact factor: 10.047
  7 in total
  4 in total

1.  The FLAM regimen: revisiting time sequential induction therapy for patients with poor-risk acute myeloid leukemia.

Authors:  Steven Knapper
Journal:  Haematologica       Date:  2015-09       Impact factor: 9.941

Review 2.  Bone marrow evaluation for diagnosis and monitoring of acute myeloid leukemia.

Authors:  Mary-Elizabeth Percival; Catherine Lai; Elihu Estey; Christopher S Hourigan
Journal:  Blood Rev       Date:  2017-02-02       Impact factor: 8.250

3.  Randomized multicenter phase II study of flavopiridol (alvocidib), cytarabine, and mitoxantrone (FLAM) versus cytarabine/daunorubicin (7+3) in newly diagnosed acute myeloid leukemia.

Authors:  Joshua F Zeidner; Matthew C Foster; Amanda L Blackford; Mark R Litzow; Lawrence E Morris; Stephen A Strickland; Jeffrey E Lancet; Prithviraj Bose; M Yair Levy; Raoul Tibes; Ivana Gojo; Christopher D Gocke; Gary L Rosner; Richard F Little; John J Wright; L Austin Doyle; B Douglas Smith; Judith E Karp
Journal:  Haematologica       Date:  2015-05-28       Impact factor: 9.941

4.  Molecular Measurable Residual Disease Testing of Blood During AML Cytotoxic Therapy for Early Prediction of Clinical Response.

Authors:  Hong Yuen Wong; Anthony D Sung; Katherine E Lindblad; Sheenu Sheela; Gregory W Roloff; David Rizzieri; Meghali Goswami; Matthew P Mulé; Nestor R Ramos; Jingrong Tang; Julie Thompson; Christin B DeStefano; Kristi Romero; Laura W Dillon; Dong-Yun Kim; Catherine Lai; Christopher S Hourigan
Journal:  Front Oncol       Date:  2019-01-15       Impact factor: 6.244
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.